Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Fesomersen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Fesomersen is a ASO targeting F11, at Pending. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.
Latest Hotspot
8 min read
Ranibizumab (Genentech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ranibizumab (Genentech) is a Fab fragment targeting VEGF-A, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Beremagene geperpavec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Beremagene geperpavec is a Gene therapy targeting COL7A1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Vixarelimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Vixarelimab: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Zidesamtinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Zidesamtinib is a Small molecule drug targeting ROS1, at NDA/BLA. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Semorinemab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Semorinemab is a Monoclonal antibody targeting TAU, at Discontinued. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.
Latest Hotspot
8 min read
Betibeglogene autotemcel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Betibeglogene autotemcel is a Gene therapy, Hematopoietic stem cell therapy targeting β-globin, at Approved. This 2026 report reviews clinical evidence.
Latest Hotspot
8 min read
Lovotibeglogene autotemcel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Lovotibeglogene autotemcel is a Gene therapy targeting β-globin, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Vericiguat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Vericiguat is a Small molecule drug targeting sGC, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Dostarlimab-gxly Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Dostarlimab-gxly is a Monoclonal antibody targeting PD-1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Orilanolimab(Syntimmune, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Orilanolimab(Syntimmune, Inc.) is a Monoclonal antibody targeting FcRn, at Discontinued. This 2026 report reviews clinical evidence, IP, deals, risks.
Latest Hotspot
8 min read
Riliprubart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Riliprubart is a Monoclonal antibody targeting C1S, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.